Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript March 7, 2024 OptiNose, Inc. beats earnings expectations. Reported EPS is $-9.0E-5, expectations were $-0.1. OPTN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by. […]